Conference Call with Black Rose Industries Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript.
Specialty Chemicals company Black Rose Industries declares Q3FY22 result: Q3 FY22 saw demand in the Indian chemical market pick up initially and slow down towards the end with the third wave of COVID. Prices of some distribution products started to fall during the quarter due to increased domestic inventory, despite international prices remaining stable. Revenue and profit in the manufacturing business increased with improved demand for acrylamide and a surge in sales of polyacrylamide liquids. The company has improved upon all the significant parameters, and as can be seen, the company is now practically a zero-debt company. Result PDF
Conference Call with Black Rose Industries Management and Analysts on Q2FY22 Performance and Outlook. Listen to the full earnings transcript.
Highlights: As expected, the quarter saw shortages of various chemicals caused by the reduced imports by several market players during Q1 FY22. In such a scenario, the company’s strong inventory position helped the company boost its revenue as well as market share in chemicals such as acrylonitrile, isophthalic acid, ethanolamines and acrylamide. Higher sales translated into higher profits, and reduced margins in the distribution business were compensated by better margins in the manufacturing business Sales of acrylamide increased by 27% over the previous quarter and prices continued to rise on the back of tight domestic supply. The international price of acrylonitrile was rangebound within $2200 - $2400/MT during the quarter. While export freight costs remained high and limited loading space was available on outbound vessels, exports formed 35% of total acrylamide sales for the quarter. We expect both sales and exports to be significantly higher when these logistics issues are eventually resolved. Result PDF
Conference Call with Black Rose Management and Institutional Investors. Listen to the full transcript.